A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Michael Rose
Michael Rose
Michael Rose
| Share Statistics | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,009.5 | $251.9 | 54% |
|
| Shares Out (Mil) | 240.0 | 50.8 | 80% |
|
| Institutional Ownership | 97.7% | 92.0% | 75% |
|
| Float (Mil) | 226.7 | 40.5 | 76% |
|
| Beta | 0.82 | 0.95 | 48% |
|
| Avg Daily Volume (000s) | 2,565 | 447 | 86% |
|
| Price Change (52-week) |
(52.5%) | 54.2% | 15% |
|
| Growth | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 64.6% | 14.0% | 97% |
|
| Net Income (5yr) | 31.6% | (9.8%) | 86% |
|
| EPS (5yr) | 21.8% | 16.3% | 71 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (15.6%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | $0.163 | $0.797 | $0.985 | |
| Month Ago EPS | $0.173 | $0.813 | $0.998 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.230 | $0.953 | $1.263 | |
| Year/Year Chg | (14.2%) | 32.8% | 100.0% | |
| Financials | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $510 | $39 | 42% |
|
| Net Income (TTM) (Mil) | $165 | ($43) | 66% |
|
| EPS (TTM) | $0.695 | ($1.600) | 57% |
|
| Operating Cash Flow (TTM) (Mil) | $128 | ($30) | 55% |
|
| Net Cash Flow (TTM) (Mil) | $67 | $3 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $200 | $5 | 50% |
|
| Enterprise Value (Q1) (Mil) | $1,960 | $182 | 49% |
|
| Valuation | ADMA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.16 | 2.60 | 79% |
|
| P/E | 12.7 | 18.6 | 26% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.6 | 0.9 | 28% |
|
| Ratios | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.3% | 63.8% | 74% |
|
| Net Margin | 32.4% | (64.7%) | 91% |
|
| ROA | 28.1% | (49.7%) | 98% |
|
| ROE | 43.3% | (55.4%) | 92% |
|
| Liabilities to Assets | 41.3% | 30.3% | 32% |
|
| F-Score | 5 | 3 | 51% |
|
ADMA Biologics, Inc. did not pass any screens on 7/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
